CL2019001280A1 - Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). - Google Patents
Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).Info
- Publication number
- CL2019001280A1 CL2019001280A1 CL2019001280A CL2019001280A CL2019001280A1 CL 2019001280 A1 CL2019001280 A1 CL 2019001280A1 CL 2019001280 A CL2019001280 A CL 2019001280A CL 2019001280 A CL2019001280 A CL 2019001280A CL 2019001280 A1 CL2019001280 A1 CL 2019001280A1
- Authority
- CL
- Chile
- Prior art keywords
- nafld
- nash
- treatment
- pirfenidone
- pfd
- Prior art date
Links
- 208000004930 Fatty Liver Diseases 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title 1
- 229960003073 pirfenidone Drugs 0.000 title 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 abstract 1
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 abstract 1
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 abstract 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 210000002824 peroxisome Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE RELACIONA CON EL USO DE UNA COMPOSICIÓN FARMACÉUTICA EN FORMA DE COMPRIMIDOS DE LIBERACIÓN PROLONGADA QUE CONTIENEN PIRFENIDONA PARA EL TRATAMIENTO DE NAFLD/NASH Y LA FIBROSIS HEPÁTICA AVANZADA, MEDIANTE LA DISMINUCIÓN SÉRICA DE COLESTEROL Y TRIGLICÉRIDOS, ASÍ COMO LA DISMINUCIÓN DEL CONTENIDO DEL ACÚMULO DE GRASA HEPÁTICA, TANTO EN LA FORMA DE MACROESTEATOSIS COMO MICROESTEATOSIS. ADICIONALMENTE, SU USO COMO AGONISTA PARA PPARGAMMA (PEROXISOMA PROLIFERACIÓN RECEPTOR ACTIVADO GAMMA), PPARALFA (PEROXISOMA PROLIFERACIÓN RECEPTOR ACTIVADO ALFA), LXR Y CPT1, MOLÉCULAS CLAVE EN EL METABOLISMO DE DEGRADACIÓN DE LAS GRASAS E INFLAMACIÓN HEPÁTICAS. ASIMISMO, OTRO USO ADICIONAL CONSISTE EN LA INDUCCIÓN DE LA DISMINUCIÓN DE LA EXPRESIÓN DEL GEN MAESTRO NFKB, FACTOR TRANSCRIPCIONAL INDUCTOR DEL PROCESO INFLAMATORIO HEPÁTICO. TODOS ESTOS EVENTOS RESULTAN EN LA REVERSIÓN DE NAFLD/NASH Y LA FIBROSIS HEPÁTICA AVANZADA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016014775A MX364040B (es) | 2016-11-11 | 2016-11-11 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001280A1 true CL2019001280A1 (es) | 2019-07-19 |
Family
ID=61193005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001280A CL2019001280A1 (es) | 2016-11-11 | 2019-05-09 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20190262325A1 (es) |
| EP (1) | EP3539537A1 (es) |
| JP (2) | JP2019535822A (es) |
| KR (2) | KR20190084056A (es) |
| CN (2) | CN115969802A (es) |
| AR (1) | AR110057A1 (es) |
| AU (2) | AU2017358367B2 (es) |
| CA (1) | CA3043300A1 (es) |
| CL (1) | CL2019001280A1 (es) |
| CO (1) | CO2019004799A2 (es) |
| EC (1) | ECSP19031851A (es) |
| IL (1) | IL266519A (es) |
| JO (1) | JOP20190102A1 (es) |
| MA (1) | MA45754A1 (es) |
| MX (1) | MX364040B (es) |
| PE (1) | PE20191149A1 (es) |
| PH (1) | PH12019501047A1 (es) |
| RU (1) | RU2019116422A (es) |
| UY (1) | UY37478A (es) |
| WO (1) | WO2018088886A1 (es) |
| ZA (1) | ZA201903012B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| EP3716975A4 (en) * | 2017-11-28 | 2022-01-12 | Eiger Biopharmaceuticals, Inc. | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
| WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
| CN116744959A (zh) * | 2020-10-23 | 2023-09-12 | 韩汇泉 | 肿瘤坏死因子-α和转化生长因子-β的双功能拮抗剂及其用途 |
| CN117007806A (zh) * | 2023-09-21 | 2023-11-07 | 中国人民解放军军事科学院军事医学研究院 | 靶向肝巨噬细胞内lxr用于控制慢乙肝进展 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| CN100542532C (zh) * | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CN102488660A (zh) * | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
| CN103550242B (zh) * | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
-
2016
- 2016-11-11 MX MX2016014775A patent/MX364040B/es active IP Right Grant
-
2017
- 2017-06-16 JO JOP/2019/0102A patent/JOP20190102A1/ar unknown
- 2017-11-09 US US16/348,189 patent/US20190262325A1/en not_active Abandoned
- 2017-11-09 RU RU2019116422A patent/RU2019116422A/ru unknown
- 2017-11-09 KR KR1020197014274A patent/KR20190084056A/ko not_active Application Discontinuation
- 2017-11-09 CA CA3043300A patent/CA3043300A1/en active Pending
- 2017-11-09 UY UY0001037478A patent/UY37478A/es not_active Application Discontinuation
- 2017-11-09 MA MA45754A patent/MA45754A1/fr unknown
- 2017-11-09 WO PCT/MX2017/000129 patent/WO2018088886A1/es active Search and Examination
- 2017-11-09 KR KR1020247015017A patent/KR20240065330A/ko active Search and Examination
- 2017-11-09 PE PE2019000946A patent/PE20191149A1/es unknown
- 2017-11-09 JP JP2019547064A patent/JP2019535822A/ja active Pending
- 2017-11-09 EP EP17840578.3A patent/EP3539537A1/en active Pending
- 2017-11-09 AU AU2017358367A patent/AU2017358367B2/en active Active
- 2017-11-09 CN CN202211265065.XA patent/CN115969802A/zh active Pending
- 2017-11-09 CN CN201780076430.3A patent/CN110248646A/zh active Pending
- 2017-11-10 AR ARP170103142A patent/AR110057A1/es unknown
-
2019
- 2019-05-08 EC ECSENADI201931851A patent/ECSP19031851A/es unknown
- 2019-05-08 IL IL266519A patent/IL266519A/en unknown
- 2019-05-09 CL CL2019001280A patent/CL2019001280A1/es unknown
- 2019-05-10 PH PH12019501047A patent/PH12019501047A1/en unknown
- 2019-05-10 CO CONC2019/0004799A patent/CO2019004799A2/es unknown
- 2019-05-14 ZA ZA2019/03012A patent/ZA201903012B/en unknown
-
2022
- 2022-09-26 JP JP2022152261A patent/JP2022173344A/ja active Pending
- 2022-11-02 US US18/051,937 patent/US20230181550A1/en active Pending
-
2024
- 2024-02-07 AU AU2024200737A patent/AU2024200737A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019116422A3 (es) | 2021-04-09 |
| AR110057A1 (es) | 2019-02-20 |
| AU2024200737A1 (en) | 2024-02-22 |
| CO2019004799A2 (es) | 2019-07-31 |
| JP2022173344A (ja) | 2022-11-18 |
| JOP20190102A1 (ar) | 2019-05-06 |
| CN115969802A (zh) | 2023-04-18 |
| PE20191149A1 (es) | 2019-09-02 |
| AU2017358367A1 (en) | 2019-05-30 |
| JP2019535822A (ja) | 2019-12-12 |
| AU2017358367B2 (en) | 2023-11-09 |
| MA45754A1 (fr) | 2019-12-31 |
| RU2019116422A (ru) | 2020-12-11 |
| IL266519A (en) | 2019-07-31 |
| MX2016014775A (es) | 2018-05-10 |
| KR20240065330A (ko) | 2024-05-14 |
| UY37478A (es) | 2018-05-31 |
| MX364040B (es) | 2019-04-11 |
| ECSP19031851A (es) | 2019-06-30 |
| EP3539537A1 (en) | 2019-09-18 |
| KR20190084056A (ko) | 2019-07-15 |
| ZA201903012B (en) | 2020-09-30 |
| PH12019501047A1 (en) | 2019-12-11 |
| CA3043300A1 (en) | 2018-05-17 |
| US20190262325A1 (en) | 2019-08-29 |
| WO2018088886A1 (es) | 2018-05-17 |
| US20230181550A1 (en) | 2023-06-15 |
| CN110248646A (zh) | 2019-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001280A1 (es) | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). | |
| IL259950B (en) | Pyrimidine derivatives for use in the treatment of cancer and inflammatory diseases | |
| CL2017000521A1 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| CL2014003444A1 (es) | Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes. | |
| GT201600010A (es) | Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MX2020005446A (es) | Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento. | |
| IL247775A0 (en) | In vivo and in vitro uses of graphene | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
| IL273550A (en) | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the I148M variant of PNPLA3 | |
| HK1256909A1 (zh) | Glp-1和其在用於治療代謝疾病的組合物中的用途 | |
| ECSP16012582A (es) | Compuestos heterocíclicos y métodos de uso | |
| BR112016021034A2 (pt) | Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit | |
| HK1243636A1 (zh) | 用於治療代謝疾病和癌症的新的線粒體解偶聯劑 | |
| PT3277295T (pt) | Composição para o tratamento de um estado metabólico patogénico da flora intestinal e de doenças derivadas | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| PL3187175T3 (pl) | Suplementacyjne preparaty terapeutyczne do sekwencyjnego lub oddzielnego podawania kwasu masłowego i probiotyków | |
| BR112017017729A2 (pt) | forma de dosagem oral de liberação controlada de agonista de receptor gaba | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2015001936A1 (es) | Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif). | |
| MX2017001293A (es) | Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino. | |
| BR112016026510A2 (pt) | Dispositivo e formulação para tratamento tópico da dor que afeta a área vulvar do órgão genital feminino | |
| PH12017500923A1 (en) | New dosage and use of a a2a antagonist | |
| BR112016026774A2 (pt) | uso de inibidores de proteassoma contendo boro após terapia de câncer primária e composição farmacêutica. | |
| BR112017018758A2 (pt) | alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide |